246 related articles for article (PubMed ID: 21880856)
1. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.
Kumar D; Kirimanjeswara G; Metzger DW
Clin Vaccine Immunol; 2011 Nov; 18(11):1925-35. PubMed ID: 21880856
[TBL] [Abstract][Full Text] [Related]
2. Protection against pneumonic plague following oral immunization with a non-replicating vaccine.
Jones A; Bosio C; Duffy A; Goodyear A; Schriefer M; Dow S
Vaccine; 2010 Aug; 28(36):5924-9. PubMed ID: 20600517
[TBL] [Abstract][Full Text] [Related]
3. Cell-mediated protection against pulmonary Yersinia pestis infection.
Parent MA; Berggren KN; Kummer LW; Wilhelm LB; Szaba FM; Mullarky IK; Smiley ST
Infect Immun; 2005 Nov; 73(11):7304-10. PubMed ID: 16239527
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
6. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
7. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.
Lin JS; Kummer LW; Szaba FM; Smiley ST
J Immunol; 2011 Feb; 186(3):1675-84. PubMed ID: 21172869
[TBL] [Abstract][Full Text] [Related]
8. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.
Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA
Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493
[TBL] [Abstract][Full Text] [Related]
9. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
10. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.
Philipovskiy AV; Smiley ST
Infect Immun; 2007 Feb; 75(2):878-85. PubMed ID: 17118978
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
[TBL] [Abstract][Full Text] [Related]
15. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
Honko AN; Sriranganathan N; Lees CJ; Mizel SB
Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759
[TBL] [Abstract][Full Text] [Related]
16. Complete Protection Against
Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
Front Immunol; 2022; 13():793382. PubMed ID: 35154110
[TBL] [Abstract][Full Text] [Related]
17. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
[TBL] [Abstract][Full Text] [Related]
18. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
[TBL] [Abstract][Full Text] [Related]
19. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
[TBL] [Abstract][Full Text] [Related]
20. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
